

1/9

FIG. 1 SDS PAGE of RSA-FAB' conjugate






FIG. 2 Pharmacokinetics of RSA-Fab' conjugate or controls in the rat



**FIG. 3 Pharmacokinetics of RSA-Fab' or Fab'-cys in the rat (assayed by ELISA or cytokine neutralisation)**

PK ANALYSIS - Winnonlin				
	$t_{1/2\alpha}(h)$	$t_{1/2\beta}(h)$	AUC (0- $\infty$ )	(h $\cdot$ $\mu$ g/ml)
L929 assay:				
RSA-Fab' conjugate	2.7	24.7	975	
Fab'-cys	ND	ND	ND	
ELISA assay:				
RSA-Fab' conjugate (ligand-albumin)	0.8	19.5	780	
RSA-Fab' conjugate (ligand-L chain)	1.3	21.6	824	
Fab'-cys	ND	0.7	4	



4/9

FIG. 4 Construction of pPIC (scFv-HSA)





FIG. 5 Reducing SDS PAGE of HSA-scFv fusion proteins



6/9

FIG. 6 Pharmacokinetics to HSA-Fab' fusion proteins or HSA in the rat






FIG. 7 Structure of trimaleimide crosslinking agent



8/9

**FIG. 8** Reducing SDS PAGE of HSA-F(ab')<sub>2</sub> conjugate



TESTED - NEGATIVE

FIG. 9 Scatchard plots of binding of RSA-F(ab')<sub>2</sub> or F(ab')<sub>2</sub> control to cell membranes

